Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

nivolumab-relatlimab

nivolumab-relatlimab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Opdualag INJECTION, INTRAVENOUS 12 mg and 4 mg/mL      
Comments:

Formulary restricted to use by oncologist in the outpatient setting only for FDA approved indications. Insurance certification to be evaluated prior to initial dose. May use patient own supply through patient assistance program if eligible.

 

Reviewed: November 2023

 

Nivolumab/Relatlimab-rmbw (Opdualag)

Last updated: Dec. 27, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved